1. Home
  2. AMS vs INAB Comparison

AMS vs INAB Comparison

Compare AMS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

N/A

Current Price

$1.08

Market Cap

10.0M

Sector

Health Care

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$0.89

Market Cap

11.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMS
INAB
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
11.8M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
AMS
INAB
Price
$1.08
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
8.1K
★ 35.4K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $19,714,000.00
N/A
Revenue This Year
$16.37
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 0.81
N/A
52 Week Low
$1.14
$0.80
52 Week High
$2.39
$2.73

Technical Indicators

Market Signals
Indicator
AMS
INAB
Relative Strength Index (RSI) 31.74 34.98
Support Level N/A N/A
Resistance Level $1.52 $1.50
Average True Range (ATR) 0.06 0.08
MACD -0.00 -0.01
Stochastic Oscillator 42.86 2.00

Price Performance

Historical Comparison
AMS
INAB

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: